Moderately hypofractionated and conventionally fractionated radiotherapy demonstrate similar efficacy, but one ...

Outranked only by skin cancer, prostate cancer is the second most common cancer in men in the U.S. Although one in every ...

Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile ...

A clinical trial co-led by Yale Urology showed high resolution micro-ultrasound is an effective tool for guiding prostate ...

Q4 2024 Earnings Call Transcript March 27, 2025 EDAP TMS S.A. beats earnings expectations. Reported EPS is $-0.05, ...

A bioengineer highlights the potential of low-intensity ultrasound for multiple uses, from enhanced drug delivery to the ...

Research reveals men skipping prostate cancer screenings are 45% more likely to die from the disease. Evidence from a large European study indicates P ...

Edap TMS SA (EDAP) reports robust HIFU revenue growth and strategic advancements, despite facing operational challenges and a ...

At Loyola Medicine, we’re working to ease those fears with an innovative, incision-free treatment option called ...

AUSTIN, Texas, March 27, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the fourth quarter and full ...

Our strong fourth quarter performance reflects our continued progress in establishing Focal One Robotic HIFU as a mainstream treatment option for the management of prostate cancer,” said Ryan Rhodes, ...

Reports revenue $21.5M, consensus $20.83M. “Our strong fourth quarter performance reflects our continued progress in establishing Focal One ...